SCHEMBL2681285

SCHEMBL2681285

Cc1nc(-c2ccccc2)cnc1N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.51
NPC1 O15118 1/20 0.51
PDGFRB P09619 1/20 0.51
KDR P35968 1/20 0.51
FLT3 P36888 1/20 0.51
RAB9A P51151 1/20 0.51
ATR Q13535 6/20 0.51
PRKDC P78527 1/20 0.49
TLR9 Q9NR96 1/20 0.49
ALOX5AP P20292 1/20 0.45
FEN1 P39748 1/20 0.45
ADORA2A P29274 2/20 0.44
AURKA O14965 1/20 0.44
HSP90AA1 P07900 1/20 0.44
PRKACA P17612 1/20 0.44
ADORA1 P30542 1/20 0.44
ALDH1A1 P00352 2/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23732500 0.85 ATR (0.50) SMN1; SMN2NPC1RAB9AATRALOX5AP
SCHEMBL29519952 0.82 ATR (0.56) SMN1; SMN2NPC1PDGFRBKDRFLT3
SCHEMBL12489014 0.82 ATR (0.56) SMN1; SMN2NPC1PDGFRBKDRFLT3
SCHEMBL15308482 0.80 HSD17B1 (0.59) ATRPRKDCADORA1HDAC6
SCHEMBL5342191 0.80 ATR (0.53) ATRALOX5APFEN1MAPT
SCHEMBL23732523 0.79 RAB9A (0.48) SMN1; SMN2NPC1RAB9AATRALOX5AP
SCHEMBL32688927 0.78 ATR (0.66) ATRPRKDCTLR9
SCHEMBL6701248 0.78 ATR (0.66) ATRPRKDCTLR9
SCHEMBL2912954 0.78 SMN1; SMN2 (0.53) SMN1; SMN2NPC1PDGFRBKDRFLT3
SCHEMBL12198431 0.78 ATR (0.56) ATRPRKDCADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028662-A1 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE PROMEGA CORP (US) 2026-01-29 US disclosed
US-12435354-B2 Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use PROMEGA CORPORATION (US) 2025-10-07 US disclosed
US-12215375-B2 Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use PROMEGA CORPORATION (US) 2025-02-04 US disclosed
US-20240158831-A1 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE PROMEGA CORPORATION 2024-05-16 US disclosed
US-11661623-B2 Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use PROMEGA CORPORATION (US) 2023-05-30 US disclosed
US-20220348983-A1 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE PROMEGA CORPORATION 2022-11-03 US disclosed
CN-106148362-B Novel coelenterazine substrates and methods of use thereof 普罗梅加公司 2021-04-30 CN disclosed
US-20200399676-A1 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE PROMEGA CORPORATION 2020-12-24 US disclosed
US-10774364-B2 Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use PROMEGA CORPORATION (US) 2020-09-15 US disclosed
EP-3498710-A1 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE Promega Corporation (US) 2019-06-19 EP disclosed
CN-103443121-A Novel coelenterazine substrates and methods of use thereof PROMEGA CORP 2013-12-11 CN disclosed
CN-103370319-A Novel coelenterazine substrates and methods of use PROMEGA CORP 2013-10-23 CN disclosed
US-20130267521-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE LLC (US) 2013-10-10 US disclosed
EP-2635582-A1 NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE Promega Corporation (US) 2013-09-11 EP disclosed
EP-2635595-A2 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE Promega Corporation (US) 2013-09-11 EP disclosed
US-20120174242-A1 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2012-07-05 US disclosed
WO-2012061529-A1 NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE PROMEGA CORPORATION (US) 2012-05-10 WO disclosed
WO-2012061530-A2 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE PROMEGA CORPORATION (US) 2012-05-10 WO disclosed
US-20120117667-A1 NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2012-05-10 US disclosed
WO-2007096764-A2 BICYCLIC HETEROARYL DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS GLENMARK PHARMACEUTICALS S.A. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120117667-A1 NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE RNGTT, UPF1, NSUN2 SMN1; SMN2 1197/4885NPC1 3503/4885PDGFRB 4290/4885
US-12435354-B2 Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use RNGTT, UPF1, LUC7L2 SMN1; SMN2 1150/4885NPC1 3344/4885PDGFRB 3965/4885
US-10774364-B2 Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use RNGTT, UPF1, LUC7L2 SMN1; SMN2 1150/4885NPC1 3344/4885PDGFRB 3965/4885
US-20220348983-A1 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE RNGTT, UPF1, LUC7L2 SMN1; SMN2 1150/4885NPC1 3344/4885PDGFRB 3965/4885
US-20240158831-A1 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE RNGTT, UPF1, LUC7L2 SMN1; SMN2 1150/4885NPC1 3344/4885PDGFRB 3965/4885
US-11661623-B2 Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use RNGTT, UPF1, LUC7L2 SMN1; SMN2 1150/4885NPC1 3344/4885PDGFRB 3965/4885
US-12215375-B2 Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use RNGTT, UPF1, LUC7L2 SMN1; SMN2 1150/4885NPC1 3344/4885PDGFRB 3965/4885
US-20260028662-A1 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE RNGTT, VIP, PREP SMN1; SMN2 1912/4885NPC1 2704/4885PDGFRB 3630/4885
US-20200399676-A1 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE RNGTT, UPF1, LUC7L2 SMN1; SMN2 1150/4885NPC1 3344/4885PDGFRB 3965/4885
US-20130267521-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB SMN1; SMN2 1464/4885NPC1 1044/4885PDGFRB 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.